<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625102</url>
  </required_header>
  <id_info>
    <org_study_id>GHHBV-2-001</org_study_id>
    <nct_id>NCT03625102</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golden Biotechnology Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatitis B virus infection is a worldwide disease and is still the most common cause of&#xD;
      hepatocellular carcinoma (HCC).Existing treatments for hepatitis B infection have various&#xD;
      side-effects including renal toxicity and drug resistance or failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis B virus infection is a worldwide disease and is still the most common cause of&#xD;
      hepatocellular carcinoma (HCC). Those carriers in China account for 33% of all chronic&#xD;
      carriers globally. A big epidemiological study of patients with chronic hepatitis B has&#xD;
      revealed that baseline HBV DNA level or cirrhosis is an independent predictor for the&#xD;
      occurrence of HCC.&#xD;
&#xD;
      Antroquinonol is a new chemical entity isolated from the mycelium of Antrodia camphorata,&#xD;
      which showed interesting anticancer and anti-inflammatory activities.Previous studies have&#xD;
      indicated that signaling molecules, such as PI3K, AMPK, and mTOR, participate in&#xD;
      Antroquinonol-induced cancer cell death, whereas Nrf2 and NF-kB are involved in the&#xD;
      anti-inflammatory effects of Antroquinonol. Moreover, we also found the administration of&#xD;
      Antroquinonol also differentially modulated T cell activity and reduced IL-18 production, but&#xD;
      enhanced the activation of Nrf2 and, thus, suppressed oxidative stress by animal studies.&#xD;
      These results demonstrate the potential applications of Antroquinonol in treating hepatitis&#xD;
      B.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-center, phase IIa, double blind, and randomized, placebo-controlled trial of Antroquinonol in patients with hepatitis B infection. Subjects with diagnosis of hepatitis B meet inclusion/exclusion criteria will be randomized into 3 groups:&#xD;
Antroquinonol 100 mg PO BID&#xD;
Antroquinonol 50 mg PO BID&#xD;
Placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percentage improvement between baseline and day 85 in quantitative HBsAg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IU/mL</measure>
    <time_frame>4 week</time_frame>
    <description>Sserum hapatitis B virus DNA level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>score</measure>
    <time_frame>12 week</time_frame>
    <description>The Fibrosis-4 score helps to estimate the amount of scarring in the liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unit/L</measure>
    <time_frame>4 week</time_frame>
    <description>Glutamic Oxaloacetic Transaminase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unit /L</measure>
    <time_frame>4 week</time_frame>
    <description>Glutamic Pyruvic Transaminase</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HBV</condition>
  <arm_group>
    <arm_group_label>Antroquinonol 100 mg PO BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antroquinonol (Hocena) 50mg/capsule. 2 capsules antroquinonol, twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antroquinonol (Hocena) 50mg/capsule. 1 capsule antroquinonol and 1 capsule placebo,twice a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule, 2 capsules placebo, twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antroquinonol</intervention_name>
    <description>Antroquinonol will be provided as a capsule-shaped which contain 50 mg Antroquinonol.</description>
    <arm_group_label>Antroquinonol 100 mg PO BID</arm_group_label>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <other_name>Hocena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects</description>
    <arm_group_label>Antroquinonol 50 mg PO BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic HBV infection patients between the ages of 20 and 75 years with serum&#xD;
             hepatitis B surface antigen(HBsAg) positivity for more than 6 months&#xD;
&#xD;
          2. BMI≦35&#xD;
&#xD;
          3. HBsAg≧10 IU/mL and HBV DNA≧2000 IU/mL.&#xD;
&#xD;
          4. AST or ALT≧25 IU and ALT&lt;5xULN&#xD;
&#xD;
          5. Female subject must use effective methods of contraception.&#xD;
&#xD;
          6. No abnormal finding of clinical relevance&#xD;
&#xD;
          7. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of hepatic decompensation such as:&#xD;
&#xD;
               1. Coagulopathy defined as prolongation of prothrombin time greater than 3 seconds&#xD;
&#xD;
               2. Total bilirubin of 2 times the upper limit of normal&#xD;
&#xD;
               3. FIB-4 of 3.25 or greater&#xD;
&#xD;
          2. Abnormal hematological and biochemical parameters at screening A、 White blood cell&#xD;
             count less than 2500 cells/uL B、 Absolute neutrophil count (ANC) less than 1,000&#xD;
             cells/mm3 (less than 750 mm3 for African or African-American subjects) C、 Hemoglobin&#xD;
             less than 12 g/dL for males, less than 11 g/dL for females D、 Estimated GFR less than&#xD;
             50 mL/min&#xD;
&#xD;
          3. Suspected or confirmed liver diseases from etiologies other than HBV (such as alcohol,&#xD;
             toxin, drug, shock, acute viral hepatitis A or E), co-infection with human&#xD;
             immunodeficiency virus, hepatitis C virus or hepatitis delta virus, prior antiviral&#xD;
             treatment with NUCs or interferon, and recent immunosuppressive therapy (including&#xD;
             chemotherapy and systemic corticosteroid).&#xD;
&#xD;
          4. Immunodeficiency disorders or severe autoimmune disease&#xD;
&#xD;
          5. Severe pulmonary disorders or significant cardiac diseases&#xD;
&#xD;
          6. Gastrointestinal disorder with post-operative condition that could interfere with drug&#xD;
             absorption&#xD;
&#xD;
          7. Significant psychiatric illness that in the judgment of the Investigator, is a&#xD;
             contraindication to protocol participation or impairs a volunteer's ability to give&#xD;
             informed consent&#xD;
&#xD;
          8. Any malignancy diagnosed within 5 years or evidence of hepatocellular carcinoma (e.g.,&#xD;
             α fetoprotein &gt; 50ng/mL or radiologic evidence)&#xD;
&#xD;
          9. Solid organ transplantation&#xD;
&#xD;
         10. Current drug or alcohol abuse&#xD;
&#xD;
         11. Pregnancy or lactation&#xD;
&#xD;
         12. Under hepatitis B antiviral or interferon treatment within 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Pin Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei-Ni Chen, MD</last_name>
    <phone>886-2-28086006</phone>
    <email>pnchen79@goldenbiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>CHUN-CHUAN Chang</last_name>
    <phone>886-2-28086006</phone>
    <email>heroman@goldenbiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ching-Pin Lin, MD</last_name>
      <phone>886-4-24739595</phone>
    </contact>
    <contact_backup>
      <last_name>Hsuan-Yi Chen</last_name>
      <phone>886-4-24739595</phone>
      <email>circlerank@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antroquinonol</keyword>
  <keyword>Hocena</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

